"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.
GCTB generally occurs in a"...
(hydroxyamphetamine Hydrobromide 1% and tropicamide 0.25%)
Convenient One-Drop Solution for Dilation
- Convenient one-drop formulation is easier to administer than many current regimens consisting of a drop from two separate products.
For Patient and Practitioner Convenience
- Formulated to work quickly to fit busy patients' schedules and your patient flow.
- Only partial loss of accommodation, due to lower (0.25%) concentration of tropicamide.
- Minimizes inconvenience: Recovery begins within 90 minutes, with complete recovery typically in 6 to 8 hours.
PAREMYD® (hydroxyamphetamine hydrobromide, tropicamide) Solution should not be used in patients with angle-closure glaucoma or in those with narrow angles in whom dilation of the pupil may precipitate an attack of angle-closure glaucoma. This product is also contraindicated in patients who are hypersensitive to any of its components.
Additional Paremyd Information
Report Problems to the Food and Drug Administration
Find out what women really need.